Header Logo

Connection

Paolo Gattuso to Receptor, ErbB-2

This is a "connection" page, showing publications Paolo Gattuso has written about Receptor, ErbB-2.
Connection Strength

0.848
  1. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl Immunohistochem Mol Morphol. 2003 Jun; 11(2):120-4.
    View in: PubMed
    Score: 0.218
  2. Non-human-papillomavirus-related malignancies of the vulva: A clinicopathological study. J Cutan Pathol. 2020 Oct; 47(10):917-922.
    View in: PubMed
    Score: 0.179
  3. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer. Acta Cytol. 2017; 61(2):140-144.
    View in: PubMed
    Score: 0.141
  4. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma. Appl Immunohistochem Mol Morphol. 2016 Nov/Dec; 24(10):738-743.
    View in: PubMed
    Score: 0.138
  5. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2.
    View in: PubMed
    Score: 0.067
  6. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001 Oct; 182(4):389-92.
    View in: PubMed
    Score: 0.049
  7. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999 Jan; 111(1):59-69.
    View in: PubMed
    Score: 0.040
  8. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries. Hum Pathol. 2005 May; 36(5):536-45.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.